Cartalax

Cartalax is a short Khavinson bioregulator peptide studied for cartilage support, extracellular-matrix regulation, and connective-tissue homeostasis.

Profile · 01

Overview

Cartalax is a synthetic tripeptide bioregulator with the sequence Ala-Glu-Asp, studied for cartilage and connective-tissue support. It is described within the Khavinson peptide framework and is not FDA-approved for any indication.

Most support comes from in vitro, preclinical, and observational literature discussing fibroblast proliferation markers, extracellular-matrix maintenance, and anti-apoptotic signaling. This page presents an educational once-daily subcutaneous protocol based on the supplied markdown source.

At a Glance

Goal
Support cartilage integrity, connective-tissue repair, and extracellular-matrix balance
Categories
Connective TissueCartilage SupportBioregulatorAnti-Aging
Synergistic
BPC-157 · GHK-Cu · Collagen peptides · Chonluten
Profile · 02

Protocol

Suggested daily titration approach starting lower and increasing every two weeks.

Reconstitute
Add 3.0 mL bacteriostatic water to a 20 mg vial for about 6.67 mg/mL concentration
Typical daily range
2-5 mg once daily
Start
2 mg daily for Weeks 1-2
Target
4-5 mg daily by Weeks 5-12
Frequency
Once per day (subcutaneous)
Cycle Length
8-12 weeks; optional extension to 16 weeks
Timing
Any consistent time; rotate injection sites
Route
Subcutaneous
Cycle
8-12 weeks on, 4 weeks off

Inject once daily subcutaneously using the 3.0 mL dilution to keep measurements practical. The protocol is largely extrapolated from bioregulator research rather than large randomized clinical trials, so the evidence base is more mechanistic than outcome-driven.

Dose progression

Weeks 1-2
2 mg · 30 units (0.30 mL)
Weeks 3-4
3 mg · 45 units (0.45 mL)
Weeks 5-8
4 mg · 60 units (0.60 mL)
Weeks 9-12
5 mg · 75 units (0.75 mL)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Science · 01

How Cartalax works.

Cartalax corresponds to a sequence motif discussed in relation to type XI collagen alpha-1 and cartilage architecture. Preclinical discussion focuses on fibroblast proliferation markers, extracellular-matrix regulation, collagen-related gene expression, and anti-apoptotic signaling.

The Khavinson bioregulator framework proposes that short peptides may influence gene expression relevant to tissue homeostasis. Human clinical evidence remains limited compared with the amount of mechanistic and cell-based literature.

Science · 02

Effects

Observations from clinical or preclinical literature.

May support connective-tissue and cartilage homeostasis based on preclinical literature
Research discussion includes MMP-9 modulation and collagen-related gene-expression effects
May support fibroblast proliferation and reduced senescence signaling in cell models
Observational literature generally describes Khavinson peptides as well tolerated
Mild injection-site reactions such as redness or itching may occur
Large-scale human randomized trial data remain unavailable
Science · 03

Caution

Use caution in people with active cancer or a history of cancer because the literature discusses proliferative signaling
Not recommended during pregnancy or breastfeeding because safety data is insufficient
Use caution with immunosuppressive therapy or complex autoimmune conditions
Consult a qualified healthcare provider before use if you have chronic medical conditions

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Vitamin C
Essential for collagen synthesis and connective-tissue repair.
Glucosamine and chondroitin
May complement cartilage-support goals.
Zinc
Supports extracellular-matrix enzyme systems and tissue healing.
Omega-3 fatty acids
Support inflammatory balance relevant to joint and connective tissue.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Maintain adequate protein and micronutrient intake to support connective-tissue remodeling
Use low-impact exercise and mobility work to reinforce joint function
Prioritize sleep and stress management to support tissue repair
Use condition-specific rehab guidance where appropriate
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Joint mobility and flexibility - track range-of-motion changes over time
  2. Pain and stiffness - monitor subjective symptom trends
  3. Functional capacity - note activity limitations that improve or worsen
  4. Injection-site reactions - track redness, swelling, or discomfort
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

CRP (C-Reactive Protein)
General inflammation marker for baseline and follow-up.
ESR
Secondary inflammatory marker that can complement CRP.
CBC (Complete Blood Count)
General monitoring and baseline screening.
CMP (Comprehensive Metabolic Panel)
Assesses liver and kidney function during peptide use.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 20 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and injection site with alcohol and allow them to dry
Pinch a skinfold and insert the needle at 45-90 degrees into subcutaneous tissue
Do not aspirate for subcutaneous injections; inject slowly and steadily
Rotate sites systematically across the abdomen, thighs, and upper arms
Discard used syringes immediately in a sharps container

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use a new sterile insulin syringe for each injection and dispose of it safely
Per-injection volume should stay within generally tolerated subcutaneous ranges
Document dose, injection site, and connective-tissue symptom trends for consistency
Human evidence is limited relative to the preclinical and observational literature
PepTribe is an educational platform. This information is for research and learning purposes only and is not medical advice.
Reference · 02

References

  1. International Journal of Molecular Sciences
    Khavinson-related peptide regulation and aging review literature.
    https://www.mdpi.com/journal/ijms
  2. Bulletin of Experimental Biology and Medicine
    Short-peptide effects on fibroblast aging and extracellular-matrix regulation.
    https://pubmed.ncbi.nlm.nih.gov/
  3. Signal Transduction and Targeted Therapy
    Therapeutic peptides review.
    https://www.nature.com/articles/s41392-022-00904-4
  4. CDC
    Subcutaneous injection route guidance.
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
  5. WHO (NCBI Bookshelf)
    Injection-safety guidance for subcutaneous administration.
    https://www.ncbi.nlm.nih.gov/books/NBK390474/
On this page